Julian Adams, PhD | Authors

Articles

The DYNAMO Trial: IPI-145 for Refractory Indolent Non-Hodgkin Lymphoma

July 03, 2014

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.